What happens when Carcinoid Tumors treatment stops working

When Carcinoid Tumor Treatment Stops Working

This is an important question, and understanding your options when treatment becomes less effective is crucial for managing your care. Let me walk you through what typically happens and what approaches your medical team might consider.

How Doctors Recognize Treatment Failure

According to the NCCN Guidelines for Neuroendocrine Tumors, doctors monitor your response through:

• Biochemical markers: Regular 24-hour urine or plasma 5-HIAA testing (measures serotonin levels)
• Imaging studies: CT or MRI scans every 12 weeks to 12 months to track tumor size and progression
• Symptom assessment: Tracking whether your carcinoid syndrome symptoms (flushing, diarrhea) are controlled
• Clinical evaluation: Overall disease progression and how you're tolerating treatment

When these markers show "clinically significant disease progression," your oncology team will reassess your treatment strategy.

General Treatment Approaches When Initial Therapy Stops Working

For Somatostatin Analogs (Octreotide LAR or Lanreotide)

If you're on standard doses and experiencing breakthrough symptoms or tumor growth, the NCCN Guidelines outline several options:

Dose Escalation:

• Higher doses of octreotide LAR (up to 60 mg monthly) or lanreotide (up to 120 mg every 14 days) may be tried
• Short-acting octreotide (100-250 mcg) can be added for breakthrough symptoms
• This approach is particularly useful if you have hormone-related symptoms

Additional Symptom Control Medications:

• Telotristat (250 mg three times daily) - specifically for refractory diarrhea that doesn't respond to standard somatostatin analogs
• Serotonin antagonists like ondansetron for diarrhea
• Non-specific antidiarrheals (loperamide, diphenoxylate/atropine)

For Tumor Control - Systemic Therapy Options

According to NCCN Guidelines, when progression occurs on somatostatin analogs, doctors typically consider:

Targeted Therapies:

• Everolimus (Afinitor) - an mTOR inhibitor that slows tumor growth (Category 1 recommendation for nonfunctional lung NETs)
• Cabozantinib - particularly if you've already tried everolimus (Category 1 if prior everolimus treatment)

Peptide Receptor Radionuclide Therapy (PRRT):

• Lutetium Lu-177 dotatate - a nuclear medicine treatment that targets somatostatin receptors on tumor cells
• Used when tumors are SSTR-positive (have somatostatin receptors) and you've progressed on standard somatostatin analogs
• This is an FDA-approved treatment with established efficacy in neuroendocrine tumors

Chemotherapy Options: For intermediate-grade or atypical carcinoid tumors, or when other options have been exhausted:

• Carboplatin + etoposide
• Cisplatin + etoposide
• Temozolomide (with or without capecitabine)

For Liver-Predominant Disease

If your cancer is mainly in the liver, the NCCN Guidelines specifically recommend:

• Hepatic arterial embolization (blocking blood flow to tumors in the liver)
• Cytoreductive surgery (removing as much tumor as possible)
• These approaches can be highly effective for controlling both tumor burden and carcinoid syndrome symptoms

Important Clinical Considerations

Multidisciplinary Approach: The NCCN Guidelines emphasize that treatment decisions should involve discussion with your entire care team, including:

• Medical oncologist
• Interventional radiologist (if liver-directed therapy is considered)
• Cardiologist (if carcinoid heart disease is present)
• Gastroenterologist or pulmonologist (depending on tumor location)

Carcinoid Syndrome Management: Even if tumor-directed therapy changes, managing your symptoms remains important. The guidelines note that diarrhea can be multifactorial—sometimes it's from the tumor, sometimes from the medication itself, pancreatic insufficiency, or bile acid issues. Your doctor may need to investigate the cause.

Monitoring for Carcinoid Heart Disease: If you have carcinoid syndrome, regular echocardiograms are essential:

• Every 1-3 years if no heart disease present
• At least annually if carcinoid heart disease is established

Questions to Ask Your Oncology Team

When discussing treatment progression with your doctor, consider asking:

1. "What specific findings show my current treatment isn't working as well?" (tumor growth rate, biomarker changes, symptom breakthrough?)

2. "Am I a candidate for PRRT with lutetium Lu-177 dotatate, and if so, what would that involve?"

3. "Would dose escalation of my current somatostatin analog be worth trying before switching to a different drug?"

4. "Is my disease primarily in the liver, and would I be a candidate for hepatic arterial embolization or surgery?"

5. "Are there clinical trials available for my specific type of carcinoid tumor?" (NCCN Guidelines note clinical trials are often preferred options)

6. "How will we monitor whether the new treatment is working, and how often will we reassess?"

7. "What are the side effects of the next treatment option compared to what I'm currently taking?"

The Bottom Line

Treatment progression in carcinoid tumors doesn't mean you're out of options. The NCCN Guidelines outline multiple sequential approaches, and newer therapies like PRRT have significantly improved outcomes. The key is catching progression early through regular monitoring and having an open conversation with your team about next steps.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.